SCHEMBL3600301

SCHEMBL3600301

N#Cc1ccc(-c2csc(-c3ccccc3Cl)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.56
CDC25B P30305 1/20 0.56
CDC25C P30307 1/20 0.56
AR P10275 1/20 0.55
GAA P10253 2/20 0.54
CYP1A1 P04798 1/20 0.52
CYP1B1 Q16678 1/20 0.52
EIF4E P06730 6/20 0.52
KDM4E B2RXH2 3/20 0.50
CYP19A1 P11511 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.48
MAPT P10636 2/20 0.48
KMT2A Q03164 2/20 0.48
LMNA P02545 1/20 0.48
ALDH1A1 P00352 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28522857 0.83 CYP19A1 (0.59) ARCYP1A1CYP1B1EIF4EKDM4E
SCHEMBL3605142 0.82 CDC25A (0.69) CDC25ACDC25BCDC25CARGAA
SCHEMBL15588908 0.76 CYP2A6 (0.58) ARKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL31245782 0.76 CYP2A6 (0.58) ARKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL14797104 0.75 EIF4E (0.67) CDC25ACDC25BCDC25CEIF4EKDM4E
SCHEMBL23743150 0.75 CDC25A (0.68) CDC25ACDC25BCDC25CGAACYP1A1
SCHEMBL23657533 0.74 CDC25A (0.62) CDC25ACDC25BCDC25CARGAA
SCHEMBL23743157 0.73 RAB9A (0.71) CDC25ACDC25BCDC25CGAAKDM4E
SCHEMBL3609748 0.73 KDM4E (0.46) CYP1A1CYP1B1EIF4EKDM4ECYP19A1
SCHEMBL28065324 0.72 GRM5 (0.48) L3MBTL1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101663298-A Thiazole derivatives as modulators of g protein-coupled receptors IRM LLC 2010-03-03 CN disclosed
US-20100022592-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2010-01-28 US disclosed
US-20100022592-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2010-01-28 US disclosed
EP-2121675-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2009-11-25 EP disclosed
WO-2008103500-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022592-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS GPR119, GPR65, GPR180 CDC25A 3955/4885CDC25B 3578/4885CDC25C 3834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.